All In MedTech

Device Trial Radar · NCT02245477

Maternal Serum Vascular Endothelial Growth Factor in Pregnant Women With Foetal Growth Restriction

Evaluation of Maternal Serum VEGF in Pregnant Women With Foetal Growth Restriction

Last checked: Nov 19, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 2014

Primary completion

Jun 2021

Study completion Jun 2021

Sponsor

Lead sponsor
Beni-Suef UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 19, 2014

More device trials from this sponsor

Design

Study type
Observational
Who can join
Female only, from 20 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study we explore To explore the role of maternal serum vascular endothelial growth factor (VEGF) in pregnancies complicated by foetal growth restriction.

Conditions

  • Foetal Growth Restriction

Interventions

  • obstetric UltrasoundDevice

    Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.

  • serum Vascular Endothelial Growth FactorOther

    Maternal blood samples (10 cc) were taken from an antecubital vein. Plastic clean sterile tubes were used for collection of blood. Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count. The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes. Serum is removed and assay immediately or sample was stored at -80 degrees

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Obstetric ultrasoundTime frame: from 28 weeks gestation to 36 weeks gestation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nesreen Abdel Fattah Abdullah Shehata

    Cairo, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.